Highlights on pembro + CRT in high-risk locally advanced cervical cancer: The KEYNOTE-A18 study
Вставка
- Опубліковано 10 вер 2024
- Dr. Domenica Lorusso reports on key results from ESMO Congress 2023 on LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Produced by the European Society for Medical Oncology
oncologypro.esm...